To assess the incidence of and risk factors associated with post-herpetic neuralgia (PHN) after post-hematopoietic cell transplantation (HCT) varicella-zoster virus (VZV) infection, we conducted a retrospective chart review of 418 consecutive patients who underwent HCT between April 2005 and March 2007. Male/female ratio was 221/197, median age at HCT was 47 years (range, 0-69 years), and autologous/allogeneic/syngeneic HCT ratio was 154/263/1. Seventy-eight patients developed VZV infection after HCT. Sixty-two patients had localized zoster, 11 patients had disseminated zoster (rash like chicken pox), and 4 patients had visceral zoster. All cases were treated with acyclovir (ACV) or valacyclovir (VACV), and there was no VZV infection-related death. Twenty-seven (35%) of the 78 patients with VZV infection suffered PHN after resolution of VZV infection. Multivariate analysis showed that advanced age is the only risk factor in autologous HCT (P=0.0075; OR=1.14; 95% CI, 0.97 to 1.33). On the other hand, advanced age (P=0.0097; OR=1.06; 95% CI, 1.01 to 1.12), male gender (P=0.0055; OR=12.7; 95% CI, 1.61 to 100.1), and GVHD prophylaxis with a tacrolimus-based regimen (P=0.0092; OR=9.56; 95% CI, 1.44 to 63.3) were associated with increased risk of PHN in allogeneic HCT. This study for the first time clarified the risk of PHN in HCT recipients.
Summary (<200 words) and keywords (3-6)
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Introduction

Reactivation of varicella-zoster virus (VZV) is a common event in patients undergoing
hematopoietic cell transplantation (HCT). [1] [2] [3] [4] [5] In HCT recipients, VZV reactivation frequently occurs as localized zoster and sometimes as disseminated cutaneous lesions resembling varicella with or without visceral involvement, which results in a high mortality rate. The most common complication associated with zoster in healthy individuals is chronic and often debilitating pain called post-herpetic neuralgia (PHN), which can last for several yeas
and may reduce quality of life. Although many previous studies have shown a high incidence of VZV reactivation after HCT, the incidence and risk of PHN in HCT recipients
have not yet been clarified.
Patients and Methods
Patients.
To assess the incidence and risk factors associated with PHN after post-HCT VZV Post-herpetic neuralgia was defined as dermatomal pain that persisted beyond rash healing.
Statistical analysis. The incidence of VZV reactivation was calculated by the Kaplan-Meier method and differences between groups were compared using the log-rank test. We performed univariate analysis for comparisons between different groups of patients or clinical data using the chi square test and t-test, as appropriate. We performed Although incidences of VZV infection were not different between age groups, the incidence of PHN increased with advance of age ( Figure 3 ). Univariate analysis showed advanced age to be a risk factor in both allogeneic HCT and autologous HCT ( Table 2) . In allogeneic HCT, FK506 usage and GVHD at onset of VZV infection to were shown to be risk factors.
Results
VZV reactivation
Seventy-eight patients developed VZV infection after HCT (M/F=36
There was no significant difference between the incidence of PHN in patients in whom antiviral therapy was initiated within 24 hours of clinical onset (no Tx delay) and that in patients in whom antiviral therapy was initiated after 24 hours from onset (Tx delay).
Multivariate analysis showed that advanced age is the only risk factor in autologous HCT (P=0.0075; OR=1.14; 95% CI, 0.97 to 1.33 source, and GVHD at onset of VZV infection were not significant.
Discussion
Herpes zoster after hematopoietic cell transplantation
Reactivation of latent VZV, presenting as localized zoster or as disseminated infection, is a common and potentially serious complication in HSCT recipients. Previous studies revealed that 23% to 60% of patients could be expected to develop VZV infection after HSCT.
1-4
Analyses of risk factors such as allogeneic versus autologous transplant, graft-versus-host disease (GVHD), underlying disease, and pre-BMT irradiation have not revealed definitive associations. 1,2 In our study, age, gender, CST vs RIST, and total body irradiation did not show a definitive association with VZV infection after HCT. Tomonari et al. reported a high risk of VZV infection after cord blood transplantation (CBT). 6 In our series, CBT a similar risk of VZV infection similar to that of other stem cell sources except related bone marrow, which showed a lower risk.
Cutaneous and visceral dissemination
VZV infection after HCT sometimes progressed to systemic infection. In previous series, 2-20% of the cases of VZV infection were disseminated zoster and 3-5% of cases were visceral dissemination such as acute abdomen, pneumonitis and CNS involvement. 1 Risk of disseminated disease has not been studied in detail. Previously, we showed an association of pre-existing (before onset of VZV infection) anti-VZV IgG titer and disseminated VZV infection. disappointing once the syndrome has occurred, the importance of PHN-preventive strategies is widely recognized. HCT recipients apparently seemed to be at higher risk of
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PHN. Locksley et al. observed PHN in 25% of HCT recipients, a much higher incidence than the expected incidence of about 9% in healthy individuals. 7 Koc et al. reported that PHN and peripheral neuropathy occurred in 43% of HCT recipients. 8 There has been no report in which prevalence and precise risk of PHN after VZV infection in HCT recipients was described. Previous studies in immunocompetent individuals showed that, advanced age, acute pain severity, presence of severe rash, rash duration before consultation, greater degree of sensory impairment, ophthalmic location and psychological distress were potential predictors of PHN.
9,10
Advanced age is the strongest risk factor in immunocompetent adults. 11 The incidence of PNH was reported to be much higher in immunocompetent patients over 60 years old. 11 In HCT recipients, the incidence of PHN was higher at a younger age than that in healthy individuals. This study for the first time clarified the risk of PHN in HCT recipients. The incidence of PHN in HCT patients of a younger age (age>20yrs) was higher than that in healthy individuals. Previous observations support the belief that a decline in cell-mediated immunity to VZV can lead to a higher incidence and greater severity of herpes zoster and post-herpetic neuralgia.
12
Due to severe cellular immunoincompetence, the risk of PHN is considered to be high in HCT recipients. In our series, the incidences of VZV infection were not significantly different in males and females, but the incidence of PNH was higher in males only in allogeneic HCT recipients. The effect of gender on risk of herpes zoster or PHN is controversial.
Prophylaxis
In our series, immediate antiviral drug administration did not reduce the incidence of PHN.
A previous study in immunocompetent individuals showed that antiviral therapy reduced the severity and duration of herpes zoster but did not prevent the development of PHN. 13 One factor potentially limiting the effect of antiviral agents on chronic pain is the fact that VZV replication occurs for several days or weeks before a rash appears and a diagnosis can be made. Therefore, to prevent PHN, we should prevent VZV reactivation itself. Some studies have shown successful long-term usage of ACV for prophylaxis of VZV infection after HCT. Administration of ACV for a period as long as that immunosuppressant usage and at least 1 year after HCT even at a low dose (ACV 200-400 mg daily) successfully reduced the incidence of VZV reactivation at 1 year after HCT, but VZV reactivation after cessation of ACV administration was still high (29-32.1%). 14, 15 Another study showed that subclinical reactivation was important to reconstitute donor-derived VZV-specific immunity. 16 It has been shown that in vivo re-exposure to VZV antigens without clinical symptoms may boost immunity and thereby prevent subsequent symptomatic VZV reactivation. 16 Therefore, administration of ACV suppresses VZV reactivation but at the same time might also suppress recovery of VZV-specific immunity by preventing contact of immune cells with VZV antigen. Active immunization by a vaccine is theoretically reasonable; however, the current VZV vaccine used worldwide is a live attenuated vaccine and therefore cannot be used in HCT recipients for a period within 2 years after transplantation. 17 Inactivated varicella vaccine may be useful for the early reconstitution of adaptive immunity to VZV after HCT. 1, 18 A live attenuated vaccine does not work during anti-viral drug usage, but inactivated vaccine can be administered during prophylaxtic anti-viral drug usage. Therefore, one possible approach is to administer an inactivated VZV vaccine before the discontinuation of prophylaxtic anti-viral drug administration.
Appropriate duration of administration and dose of a prophylaxtic anti-viral drug and appropriate timing of inactivated VZV vaccine administration must be studied prospectively. 
